Morgan Stanley raised the firm’s price target on Viking Therapeutics (VKTX) to $102 from $98 and keeps an Overweight rating on the shares. The VANQUISH-1 obesity and VANQUISH-2 Type 2 diabetes plus obesity trials are enrolling ahead of schedule, notes the analyst, who also notes that management plans to meet with the FDA in an end-of-Phase 2 meeting for oral VK2735 in Q4 with a Phase 3 start targeted soon after. The firm is “encouraged by swift execution across programs,” the analyst tells investors after the company’s Q3 update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Promising Clinical Progress and Accelerated Enrollment Drive Buy Rating for Viking Therapeutics
- Viking Therapeutics offered ‘transformative’ Q3 update, says Cantor Fitzgerald
- Viking Therapeutics Advances Obesity Treatment Pipeline
- Viking Therapeutics Gains Buy Rating Amid Promising Obesity Treatment Developments and Strategic Advancements
- Viking Therapeutics reports Q3 EPS (81c), consensus (67c)